[go: up one dir, main page]

DK1718756T3 - Botulinumtoksinscreeningassays - Google Patents

Botulinumtoksinscreeningassays

Info

Publication number
DK1718756T3
DK1718756T3 DK05724048.3T DK05724048T DK1718756T3 DK 1718756 T3 DK1718756 T3 DK 1718756T3 DK 05724048 T DK05724048 T DK 05724048T DK 1718756 T3 DK1718756 T3 DK 1718756T3
Authority
DK
Denmark
Prior art keywords
methods
bont
activity
botulinumtoksinscreeningassays
fgfr3
Prior art date
Application number
DK05724048.3T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Patton E Gary
Kei Roger Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1718756T3 publication Critical patent/DK1718756T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • External Artificial Organs (AREA)
DK05724048.3T 2004-02-24 2005-02-23 Botulinumtoksinscreeningassays DK1718756T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54759104P 2004-02-24 2004-02-24
PCT/US2005/006421 WO2005082096A2 (en) 2004-02-24 2005-02-23 Botulinum toxin screening assays

Publications (1)

Publication Number Publication Date
DK1718756T3 true DK1718756T3 (da) 2012-02-27

Family

ID=34910920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05724048.3T DK1718756T3 (da) 2004-02-24 2005-02-23 Botulinumtoksinscreeningassays

Country Status (9)

Country Link
US (3) US7598027B2 (da)
EP (1) EP1718756B1 (da)
JP (1) JP4970057B2 (da)
AT (1) ATE533853T1 (da)
AU (2) AU2005216547B2 (da)
CA (1) CA2558758C (da)
DK (1) DK1718756T3 (da)
ES (1) ES2374822T3 (da)
WO (1) WO2005082096A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
EP1718756B1 (en) * 2004-02-24 2011-11-16 Allergan, Inc. Botulinum toxin screening assays
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
WO2006101809A1 (en) * 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
ES2338368T3 (es) * 2005-10-12 2010-05-06 Allergan, Inc. Ensayos de interactividad molecular o subcelular usando despolarizacion tras transferencia de energia de resonancia (daret).
JP2009543556A (ja) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
DK2271670T3 (da) 2008-03-14 2014-12-01 Allergan Inc Immunbaserede aktivitetsassays med botulinumtoksin serotype a
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2010090677A1 (en) 2008-12-10 2010-08-12 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8492109B2 (en) 2009-01-20 2013-07-23 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
US8361789B2 (en) * 2009-03-13 2013-01-29 Allergan, Inc. Cells useful for immuno-based Botulinum toxin serotype A activity assays
PL3281953T3 (pl) 2009-03-13 2020-05-18 Allergan, Inc. Oparte na reakcji immunologicznej testy aktywności przekierowanej endopeptydazy
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
ES2653249T3 (es) * 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
EP2798077A2 (en) 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
WO2013170206A1 (en) * 2012-05-11 2013-11-14 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Research & Material Command Toxin detection using stem cell derived neurons
EA029275B1 (ru) 2012-05-30 2018-03-30 Президент Энд Феллоуз Оф Гарвард Колледж Рекомбинантный ботулинический нейротоксин
US8962340B2 (en) 2012-12-03 2015-02-24 Src, Inc. Real-time assay for the detection of botulinum toxin
CA2898415A1 (en) 2013-01-16 2014-07-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP3030905B9 (en) * 2013-08-09 2024-04-03 Biomadison, Inc. Botulinum toxin assay with improved sensitivity
JP6630717B2 (ja) 2014-07-07 2020-01-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 組織試料における切断ｓｎａｐ２５の検出方法
HUE057258T2 (hu) 2015-03-26 2022-05-28 Harvard College Szerkesztett Botulinum neurotoxin
CN109715658B (zh) 2016-07-07 2023-09-12 辉瑞大药厂 可溶性成纤维细胞生长因子受体3(sfgfr3)多肽及其用途
JP7100020B2 (ja) 2016-08-24 2022-07-12 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
HRP20191966T4 (hr) 2016-09-13 2022-09-16 Allergan, Inc. Stabilizirani neproteinski klostridijalni pripravci toksina
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
KR101940500B1 (ko) * 2018-11-29 2019-01-21 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
IL300623A (en) 2020-08-21 2023-04-01 Genzyme Corp Anti-FGFR3 antibodies and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750365A (en) 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US5731161A (en) * 1995-04-24 1998-03-24 Allergan, Inc. Botulinum toxin antibody detection assay
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
IL128380A0 (en) 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
EP1218502A2 (en) * 1999-09-15 2002-07-03 Janssen Pharmaceutica N.V. Nicotinic acetylcholine receptor : alpha10 subunit
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6913877B1 (en) * 2000-09-11 2005-07-05 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for detecting bioactive compounds
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
US7415358B2 (en) * 2001-05-22 2008-08-19 Ocimum Biosolutions, Inc. Molecular toxicology modeling
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7208285B2 (en) * 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
WO2003101484A1 (en) * 2002-05-31 2003-12-11 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DE602004019814D1 (de) * 2003-12-02 2009-04-16 Ucb Pharma Sa Imidazolderivate, verfahren zu deren herstellung und deren anwendungen
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
JP4656836B2 (ja) * 2003-12-19 2011-03-23 パナソニック株式会社 同期クロック生成装置及び同期クロック生成方法
EP1718756B1 (en) * 2004-02-24 2011-11-16 Allergan, Inc. Botulinum toxin screening assays
WO2006012309A1 (en) * 2004-06-25 2006-02-02 Cold Spring Harbor Laboratory Inducible inactivation of synaptic transmission
DE602006014812D1 (de) * 2005-04-05 2010-07-22 Allergan Inc Lostridientoxinaktivität
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy

Also Published As

Publication number Publication date
US7645570B2 (en) 2010-01-12
AU2005216547A1 (en) 2005-09-09
AU2005216547B2 (en) 2009-03-12
CA2558758C (en) 2015-06-23
WO2005082096A3 (en) 2006-06-22
US7598027B2 (en) 2009-10-06
EP1718756A4 (en) 2008-06-04
ATE533853T1 (de) 2011-12-15
US20090317839A1 (en) 2009-12-24
JP4970057B2 (ja) 2012-07-04
EP1718756B1 (en) 2011-11-16
CA2558758A1 (en) 2005-09-09
AU2009202136A1 (en) 2009-06-18
EP1718756A2 (en) 2006-11-08
ES2374822T3 (es) 2012-02-22
WO2005082096A2 (en) 2005-09-09
US20080182799A1 (en) 2008-07-31
US8257914B2 (en) 2012-09-04
JP2007526770A (ja) 2007-09-20
AU2009202136B2 (en) 2011-12-22
US20080003240A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
DK1718756T3 (da) Botulinumtoksinscreeningassays
NO20210557A1 (no) Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
ATE476659T1 (de) Sensor für mehrere analyte
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
DE602006012327D1 (de) Mittel zur funktionalen wiederherstellung eines geschädigten nervensystems
FR2901806B1 (fr) Dispositif et ensemble de controle microbiologique
ATE446509T1 (de) Serumfreie expansion von zellen in kultur
DE602006013653D1 (de) System zum nachweis und zur analyse der ausbreitung biologischer abfallprodukte in unterwäsche
EP1947990A4 (en) MICROFLUIDIC CELL CULTURAL DEVICE
DE602005017876D1 (de) Brennstoffzellensystem und steuerverfahren dafür
ATE513581T1 (de) Portabler applikator zur kollagenstimulation
DK1896571T3 (da) Materialer og fremgangsmåder, der vedrører cellebaserede behandlinger
DE602006013921D1 (de) Brennstoffzelle und Brennstoffzellenanalage
EP2133342A4 (en) INHIBITOR OF PROTEINTHYROSINE PHOSPHATASE 1B, METHOD OF MANUFACTURE AND APPLICATIONS THEREOF
EP2535050A3 (en) Compositions and methods for detection of lysosomal storage disease
FI20055214L (fi) Levy, sen käyttö, järjestelmä ja levyn kiinnitysmenetelmä
WO2007103146A3 (en) Truncated proteins as cancer markers
CY1112090T1 (el) Μεθοδος για ανιχνευση βιολογικων οργανισμων με χρηση σκεδασης raman
WO2012024546A3 (en) Incorporation of health measurments in analysis and interpretation of functional biological response data
ATE553386T1 (de) Bluttypisierung
DE602005015559D1 (de) Pharmakodynamische tests mit durchflusszytometrie
ATE471147T1 (de) Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
DE602008005172D1 (de) Markierungsfreier einzelzelltest
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
DE602005015270D1 (de) Druckplattenmaterial und Druckverfahren, das dieses Material verwendet